EVI1 as a Marker for Lymph Node Metastasis in HNSCC.
Aged
Biomarkers, Tumor
/ metabolism
Case-Control Studies
Female
Gene Expression Regulation, Neoplastic
Head and Neck Neoplasms
/ metabolism
Humans
Lymphatic Metastasis
/ pathology
MDS1 and EVI1 Complex Locus Protein
/ metabolism
Male
Middle Aged
Neoplasm Staging
Prognosis
Retrospective Studies
Squamous Cell Carcinoma of Head and Neck
/ metabolism
Tissue Array Analysis
Up-Regulation
EVI1
HNSCC
biomarker
lymph node metastasis
prognosis
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Jan 2020
28 Jan 2020
Historique:
received:
04
12
2019
revised:
24
01
2020
accepted:
24
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
5
11
2020
Statut:
epublish
Résumé
HNSCC is the sixth most common cancer in humans and has still a very poor prognosis. The treatment methods so far are very often associated with mutilation and impairment in the quality of life. Except for p16 expression, there are no reliable prognostic markers in HNSCC so far. Ecotropic Viral Integration Site 1 (EVI1) is a well-described prognostic marker in leukemia and different types of solid cancers. In these, a high EVI1 expression is associated with a poor prognosis. In HNSCC, it is not known so far if EVI1 has any prognostic relevance. We used our representative tissue cohort of 389 primary HNSCCs, of which 57.2% had one or more lymph node metastases. Here EVI1 expression was analyzed via immunohistochemistry and correlated with the clinical characteristics of these patients. Although in HNSCC EVI1 expression does not predict poor survival, a high EVI1 expression in the primary tumor correlates with a lymph node metastatic disease. Consequently, EVI1 may serve as a biomarker to predict an occult lymph node metastasis in a clinical nodal negative (cN0) HNSCC.
Sections du résumé
BACKGROUND
BACKGROUND
HNSCC is the sixth most common cancer in humans and has still a very poor prognosis. The treatment methods so far are very often associated with mutilation and impairment in the quality of life. Except for p16 expression, there are no reliable prognostic markers in HNSCC so far. Ecotropic Viral Integration Site 1 (EVI1) is a well-described prognostic marker in leukemia and different types of solid cancers. In these, a high EVI1 expression is associated with a poor prognosis. In HNSCC, it is not known so far if EVI1 has any prognostic relevance.
MATERIALS AND METHODS
METHODS
We used our representative tissue cohort of 389 primary HNSCCs, of which 57.2% had one or more lymph node metastases. Here EVI1 expression was analyzed via immunohistochemistry and correlated with the clinical characteristics of these patients.
RESULTS
RESULTS
Although in HNSCC EVI1 expression does not predict poor survival, a high EVI1 expression in the primary tumor correlates with a lymph node metastatic disease.
CONCLUSION
CONCLUSIONS
Consequently, EVI1 may serve as a biomarker to predict an occult lymph node metastasis in a clinical nodal negative (cN0) HNSCC.
Identifiants
pubmed: 32013033
pii: ijms21030854
doi: 10.3390/ijms21030854
pmc: PMC7038015
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
MDS1 and EVI1 Complex Locus Protein
0
MECOM protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : PE1179/11-1
Organisme : Medinizische Fakultät der Universität zu Lübeck
ID : J26-2018
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
CA Cancer J Clin. 1996 Jan-Feb;46(1):5-27
pubmed: 8548526
N Engl J Med. 1993 Jan 21;328(3):184-94
pubmed: 8417385
Front Oncol. 2018 Aug 29;8:310
pubmed: 30211111
Histol Histopathol. 2013 May;28(5):605-10
pubmed: 23361561
Blood. 2011 Jun 9;117(23):6304-14
pubmed: 21190993
Br J Cancer. 1990 May;61(5):779-87
pubmed: 2140045
Prostate. 2000 Nov 1;45(3):207-15
pubmed: 11074522
J Hematol Oncol. 2015 Mar 21;8:28
pubmed: 25886616
Future Oncol. 2015;11(11):1675-86
pubmed: 26043219
Expert Rev Anticancer Ther. 2006 Jul;6(7):1111-8
pubmed: 16831082
Oncogene. 2014 Oct 16;33(42):5028-38
pubmed: 24747972
Int J Cancer. 2018 Sep 15;143(6):1426-1439
pubmed: 29663357
CA Cancer J Clin. 2017 Mar;67(2):122-137
pubmed: 28128848
Am J Surg. 1983 Oct;146(4):531-6
pubmed: 6625100
PLoS One. 2013 Nov 20;8(11):e80828
pubmed: 24278325
Mol Oncol. 2013 Jun;7(3):647-68
pubmed: 23517670
Leukemia. 2013 Jan;27(1):56-65
pubmed: 22828445
Nature. 2017 Mar 16;543(7645):378-384
pubmed: 28112728
J Clin Oncol. 1987 Jan;5(1):10-20
pubmed: 2433406
Cell Death Dis. 2018 Jan 16;9(2):18
pubmed: 29339729
Cancer Sci. 2012 Aug;103(8):1371-7
pubmed: 22494115
Oncogene. 2011 Mar 17;30(11):1290-301
pubmed: 21057539
Cancer Res. 2007 Apr 1;67(7):3074-84
pubmed: 17409414
Gene. 2007 Jul 15;396(2):346-57
pubmed: 17507183
Onco Targets Ther. 2017 May 26;10:2739-2744
pubmed: 28603423
Mol Carcinog. 2013 Apr;52(4):255-264
pubmed: 22161860
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):165-9
pubmed: 22231490
Proc Natl Acad Sci U S A. 2012 Feb 7;109(6):2168-73
pubmed: 22308434
Cell Death Dis. 2019 Feb 18;10(3):166
pubmed: 30778048
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Curr Opin Oncol. 2008 May;20(3):249-55
pubmed: 18391622
Int J Biochem Cell Biol. 2013 Aug;45(8):1568-76
pubmed: 23665236
Mol Cell Biol. 1988 Jan;8(1):301-8
pubmed: 2827004
Curr Opin Oncol. 2007 May;19(3):216-21
pubmed: 17414639
Oral Oncol. 2019 Jan;88:18-26
pubmed: 30616791
Oncogene. 2017 Mar;36(11):1573-1584
pubmed: 27617580